for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Mallinckrodt Announces U.S. FDA Filing Acceptance Of New Drug Application Treatment Of Hepatorenal Syndrome

April 22 (Reuters) - Mallinckrodt Plc:

* MALLINCKRODT ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR TERLIPRESSIN FOR TREATMENT OF HEPATORENAL SYNDROME TYPE 1 (HRS-1)

* MALLINCKRODT - ANTICIPATES FDA ADVISORY COMMITTEE MEETING TO DISCUSS SUBMISSION LATER IN 2020 FOR TERLIPRESSIN

* MALLINCKRODT PLC - FDA ASSIGNED A PDUFA TARGET DATE OF SEPTEMBER 12, 2020 FOR TERLIPRESSIN Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up